This is a 45-minute CFPC Mainpro+ certified accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation, red flag features, and chronic nature of GPP, including its lifelong physical, emotional, and psychosocial impacts. The role of the interleukin-36 (IL-36) receptor pathway in disease pathogenesis, and strategies for managing and preventing GPP flares will also be explored. Particular emphasis will be placed on spesolimab, a recently Health Canada-approved, first-in-class IL-36 receptor antagonist designed specifically for GPP treatment.\n<\/p>\n
This program has received financial support from Boehringer Ingelheim in the form of an unrestricted educational grant.<\/p>","protected":false},"excerpt":{"rendered":"
This is a 45-minute CFPC Mainpro+ certified accredited eCME program for Canadian HCPs. This program is designed to provide practical, evidence-based insights into the diagnosis and management of generalized pustular psoriasis (GPP), a rare, chronic skin condition with potentially life-threatening flares. Using a patient case study, this program will examine the clinical presentation, red flag […]<\/p>\n","protected":false},"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"product_brand":[],"product_cat":[],"product_tag":[],"class_list":{"0":"post-8162","1":"product","2":"type-product","3":"status-publish","6":"first","7":"instock","8":"downloadable","9":"virtual","10":"taxable","11":"purchasable","12":"product-type-simple"},"acf":[],"yoast_head":"\n